vs
西联汇款（AFG）与徕博科（LH）财务数据对比。点击上方公司名可切换其他公司
徕博科的季度营收约是西联汇款的1.7倍（$3.5B vs $2.1B），西联汇款净利率更高（14.5% vs 4.7%，领先9.8%），徕博科同比增速更快（5.6% vs -4.0%），过去两年徕博科的营收复合增速更高（5.2% vs 4.0%）
西联汇款是总部位于美国科罗拉多州丹佛市的跨国金融服务企业，为全球个人及商业客户提供跨境汇款、支付等多元金融解决方案，在全球绝大多数国家和地区拥有覆盖广泛的服务网络。
徕博科（Labcorp）是全球领先的生命科学与诊断检测企业，面向医疗机构、制药企业和个人患者提供全面的临床检验服务、药物研发支持及医疗检测解决方案，依托先进科研经验与创新技术输出准确可落地的健康洞察，助力临床决策、加快新药研发，提升全球患者健康水平。
AFG vs LH — 直观对比
营收规模更大
LH
是对方的1.7倍
$2.1B
营收增速更快
LH
高出9.6%
-4.0%
净利率更高
AFG
高出9.8%
4.7%
两年增速更快
LH
近两年复合增速
4.0%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $2.1B | $3.5B |
| 净利润 | $299.0M | $164.7M |
| 毛利率 | — | 28.2% |
| 营业利润率 | 18.4% | 7.6% |
| 净利率 | 14.5% | 4.7% |
| 营收同比 | -4.0% | 5.6% |
| 净利润同比 | 17.3% | 14.9% |
| 每股收益（稀释后） | $3.59 | $1.98 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收AFGLH
| Q4 25 | $2.1B | $3.5B | ||
| Q3 25 | $2.3B | $3.6B | ||
| Q2 25 | $1.9B | $3.5B | ||
| Q1 25 | $1.9B | $3.3B | ||
| Q4 24 | $2.1B | $3.3B | ||
| Q3 24 | $2.4B | $3.3B | ||
| Q2 24 | $1.9B | $3.2B | ||
| Q1 24 | $1.9B | $3.2B |
净利润AFGLH
| Q4 25 | $299.0M | $164.7M | ||
| Q3 25 | $215.0M | $261.1M | ||
| Q2 25 | $174.0M | $237.9M | ||
| Q1 25 | $154.0M | $212.8M | ||
| Q4 24 | $255.0M | $143.4M | ||
| Q3 24 | $181.0M | $169.3M | ||
| Q2 24 | $209.0M | $205.3M | ||
| Q1 24 | $242.0M | $228.0M |
毛利率AFGLH
| Q4 25 | — | 28.2% | ||
| Q3 25 | — | 28.8% | ||
| Q2 25 | — | 29.7% | ||
| Q1 25 | — | 28.3% | ||
| Q4 24 | — | 26.9% | ||
| Q3 24 | — | 27.6% | ||
| Q2 24 | — | 28.8% | ||
| Q1 24 | — | 28.2% |
营业利润率AFGLH
| Q4 25 | 18.4% | 7.6% | ||
| Q3 25 | 11.5% | 11.1% | ||
| Q2 25 | 11.9% | 11.2% | ||
| Q1 25 | 10.6% | 9.7% | ||
| Q4 24 | 14.9% | 6.5% | ||
| Q3 24 | 9.7% | 7.7% | ||
| Q2 24 | 14.3% | 9.2% | ||
| Q1 24 | 15.9% | 10.1% |
净利率AFGLH
| Q4 25 | 14.5% | 4.7% | ||
| Q3 25 | 9.2% | 7.3% | ||
| Q2 25 | 9.0% | 6.7% | ||
| Q1 25 | 8.3% | 6.4% | ||
| Q4 24 | 11.9% | 4.3% | ||
| Q3 24 | 7.6% | 5.2% | ||
| Q2 24 | 11.0% | 6.4% | ||
| Q1 24 | 12.7% | 7.2% |
每股收益（稀释后）AFGLH
| Q4 25 | $3.59 | $1.98 | ||
| Q3 25 | $2.58 | $3.12 | ||
| Q2 25 | $2.07 | $2.84 | ||
| Q1 25 | $1.84 | $2.52 | ||
| Q4 24 | $3.03 | $1.72 | ||
| Q3 24 | $2.16 | $2.00 | ||
| Q2 24 | $2.49 | $2.43 | ||
| Q1 24 | $2.89 | $2.69 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $1.7B | $532.3M |
| 总债务越低越好 | $1.8B | — |
| 股东权益账面价值 | $4.8B | $8.6B |
| 总资产 | $32.6B | $18.4B |
| 负债/权益比越低杠杆越低 | 0.38× | — |
8季度趋势，按日历期对齐
现金及短期投资AFGLH
| Q4 25 | $1.7B | $532.3M | ||
| Q3 25 | $1.8B | $598.1M | ||
| Q2 25 | $1.3B | $647.3M | ||
| Q1 25 | $1.3B | $369.4M | ||
| Q4 24 | $1.4B | $1.5B | ||
| Q3 24 | $1.3B | $1.5B | ||
| Q2 24 | $1.1B | $265.1M | ||
| Q1 24 | $1.1B | $99.3M |
总债务AFGLH
| Q4 25 | $1.8B | — | ||
| Q3 25 | $1.8B | — | ||
| Q2 25 | $1.5B | — | ||
| Q1 25 | $1.5B | — | ||
| Q4 24 | $1.5B | — | ||
| Q3 24 | $1.5B | — | ||
| Q2 24 | $1.5B | — | ||
| Q1 24 | $1.5B | — |
股东权益AFGLH
| Q4 25 | $4.8B | $8.6B | ||
| Q3 25 | $4.7B | $8.7B | ||
| Q2 25 | $4.5B | $8.5B | ||
| Q1 25 | $4.4B | $8.3B | ||
| Q4 24 | $4.5B | $8.1B | ||
| Q3 24 | $4.7B | $8.2B | ||
| Q2 24 | $4.4B | $8.0B | ||
| Q1 24 | $4.2B | $8.0B |
总资产AFGLH
| Q4 25 | $32.6B | $18.4B | ||
| Q3 25 | $33.8B | $18.3B | ||
| Q2 25 | $30.7B | $18.1B | ||
| Q1 25 | $30.3B | $17.6B | ||
| Q4 24 | $30.8B | $18.4B | ||
| Q3 24 | $32.6B | $18.6B | ||
| Q2 24 | $29.9B | $16.7B | ||
| Q1 24 | $30.0B | $16.5B |
负债/权益比AFGLH
| Q4 25 | 0.38× | — | ||
| Q3 25 | 0.38× | — | ||
| Q2 25 | 0.33× | — | ||
| Q1 25 | 0.34× | — | ||
| Q4 24 | 0.33× | — | ||
| Q3 24 | 0.31× | — | ||
| Q2 24 | 0.34× | — | ||
| Q1 24 | 0.35× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $784.0M | $614.2M |
| 自由现金流经营现金流 - 资本支出 | — | $490.3M |
| 自由现金流率自由现金流/营收 | — | 13.9% |
| 资本支出强度资本支出/营收 | — | 3.5% |
| 现金转化率经营现金流/净利润 | 2.62× | 3.73× |
| 过去12个月自由现金流最近4个季度 | — | $1.2B |
8季度趋势，按日历期对齐
经营现金流AFGLH
| Q4 25 | $784.0M | $614.2M | ||
| Q3 25 | $216.0M | $387.2M | ||
| Q2 25 | $191.0M | $620.6M | ||
| Q1 25 | $342.0M | $18.5M | ||
| Q4 24 | $674.0M | $777.2M | ||
| Q3 24 | $459.0M | $277.3M | ||
| Q2 24 | $-88.0M | $561.1M | ||
| Q1 24 | $107.0M | $-29.8M |
自由现金流AFGLH
| Q4 25 | — | $490.3M | ||
| Q3 25 | — | $280.5M | ||
| Q2 25 | — | $542.7M | ||
| Q1 25 | — | $-107.5M | ||
| Q4 24 | — | $665.1M | ||
| Q3 24 | — | $161.5M | ||
| Q2 24 | — | $432.9M | ||
| Q1 24 | — | $-163.6M |
自由现金流率AFGLH
| Q4 25 | — | 13.9% | ||
| Q3 25 | — | 7.9% | ||
| Q2 25 | — | 15.4% | ||
| Q1 25 | — | -3.2% | ||
| Q4 24 | — | 20.0% | ||
| Q3 24 | — | 4.9% | ||
| Q2 24 | — | 13.4% | ||
| Q1 24 | — | -5.2% |
资本支出强度AFGLH
| Q4 25 | — | 3.5% | ||
| Q3 25 | — | 3.0% | ||
| Q2 25 | — | 2.2% | ||
| Q1 25 | — | 3.8% | ||
| Q4 24 | — | 3.4% | ||
| Q3 24 | — | 3.5% | ||
| Q2 24 | — | 4.0% | ||
| Q1 24 | — | 4.2% |
现金转化率AFGLH
| Q4 25 | 2.62× | 3.73× | ||
| Q3 25 | 1.00× | 1.48× | ||
| Q2 25 | 1.10× | 2.61× | ||
| Q1 25 | 2.22× | 0.09× | ||
| Q4 24 | 2.64× | 5.42× | ||
| Q3 24 | 2.54× | 1.64× | ||
| Q2 24 | -0.42× | 2.73× | ||
| Q1 24 | 0.44× | -0.13× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
AFG
| Property And Casualty Insurance | $2.0B | 96% |
| Other | $83.0M | 4% |
LH
| Diagnostics | $2.7B | 78% |
| Biopharma Laboratory Services | $793.0M | 23% |
